Immune sparing Radiotherapy strategies In head and neck Squamous cell carcinoma (IRIS)
- Conditions
- head and neck cancer (HNC)head and neck squamous cell carcinoma (HNSCC)10027656
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 42
Inclusion Criteria
Patients with mucosal squamous cell carcinoma of the head and neck amenable for
radiotherapy
Exclusion Criteria
• Previously treated by irradiation in the head and neck region
• Chronic inflammatory disease or immune disorders
• Other malignant disease (unless in situ carcinoma or BCC) within the last 2
years.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>* Numbers of immune cell populations and frequency of T cell subsets according<br /><br>to markers of maturation, activation, co-signaling and chemo-attractant<br /><br>receptors at baseline, related to patient- and tumor characteristics (tumor<br /><br>localization, TNM status, tumor subtype, comorbidities etc.).<br /><br>* Temporal changes of immune markers obtained in blood during/after treatment<br /><br>at 6 timepoints (baseline, 2 weeks during RT, end of RT, 2 weeks after RT, 6<br /><br>weeks after RT and 3 months after RT).</p><br>
- Secondary Outcome Measures
Name Time Method <p>n.a.</p><br>